JG
STLN

Jefferies Group’s Starling Oncology STLN Stock Holding History

Jefferies Group’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-40,000
Closed -$432K – 1997
2020
Q4 		$432K Sell
40,000
-60,000
-60% -$618K ﹤0.01% 1190
2020
Q3 		$1.04M Sell
100,000
-50,593
-34% -$526K 0.01% 788
2020
Q2 		$1.51M Buy
+150,593
New +$1.5M 0.02% 655

Other funds holding STLN

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
ECM
Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return

Jefferies Group's STLN Position: Q1 2021 in Review

Jefferies Group sold out of Starling Oncology (STLN) in Q1 2021, closing a stake of 40,000 shares — an estimated $432K sold.

Jefferies Group first reported a position in STLN in Q2 2020 and held it in 3 quarters. The position peaked at $1.51M in Q2 2020. 50 funds tracked by Wall St. Rank hold STLN as of Q1 2021.

  • Jefferies Group reported no remaining Starling Oncology position as of Q1 2021 after selling out during the quarter.
  • Jefferies Group sold 40,000 Starling Oncology shares in Q1 2021, an estimated $432K.
  • Jefferies Group first reported a position in Starling Oncology in Q2 2020 and held it in 3 quarters.
  • Jefferies Group's Starling Oncology position peaked at $1.51M in Q2 2020.
  • 50 funds tracked by Wall St. Rank held Starling Oncology as of Q1 2021.

Based on Jefferies Group's 13F filing for Q1 2021, filed 14 May 2021.